187 related articles for article (PubMed ID: 31196964)
21. RASSF1A methylation is predictive of poor prognosis in female breast cancer in a background of overall low methylation frequency.
Buhmeida A; Merdad A; Al-Maghrabi J; Al-Thobaiti F; Ata M; Bugis A; Syrjänen K; Abuzenadah A; Chaudhary A; Gari M; Al-Qahtani M; Dallol A
Anticancer Res; 2011 Sep; 31(9):2975-81. PubMed ID: 21868547
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic Role of Long Non-Coding RNAs in Breast Cancer: a Systematic Review and Meta-Analysis.
Gao X; Xu J; Cao F; Chen F; Chen T; Li H; Deng Z; Xu S
Clin Lab; 2021 Mar; 67(3):. PubMed ID: 33739040
[TBL] [Abstract][Full Text] [Related]
23. Quantitative assessment of the relationship between RASSF1A gene promoter methylation and bladder cancer (PRISMA).
Zhan L; Zhang B; Tan Y; Yang C; Huang C; Wu Q; Zhang Y; Chen X; Zhou M; Shu A
Medicine (Baltimore); 2017 Feb; 96(7):e6097. PubMed ID: 28207521
[TBL] [Abstract][Full Text] [Related]
24. Circulating tumor DNA
Sun X; Li H; Sun M; Yuan Y; Sun L
Future Oncol; 2019 Oct; 15(30):3513-3525. PubMed ID: 31578881
[No Abstract] [Full Text] [Related]
25. Associations between RASSF1A promoter methylation and NSCLC: a meta-analysis of published data.
Liu WJ; Tan XH; Guo BP; Ke Q; Sun J; Cen H
Asian Pac J Cancer Prev; 2013; 14(6):3719-24. PubMed ID: 23886171
[TBL] [Abstract][Full Text] [Related]
26. Association of RASSF1A promoter methylation with lung cancer risk: a meta-analysis.
Huang YZ; Wu W; Wu K; Xu XN; Tang WR
Asian Pac J Cancer Prev; 2014; 15(23):10325-8. PubMed ID: 25556469
[TBL] [Abstract][Full Text] [Related]
27. RASSF1A and SOCS1 genes methylation status as a noninvasive marker for hepatocellular carcinoma.
Pasha HF; Mohamed RH; Radwan MI
Cancer Biomark; 2019; 24(2):241-247. PubMed ID: 30689554
[TBL] [Abstract][Full Text] [Related]
28. Association between RASSF1A promoter methylation and ovarian cancer: a meta-analysis.
Shi H; Li Y; Wang X; Lu C; Yang L; Gu C; Xiong J; Huang Y; Wang S; Lu M
PLoS One; 2013; 8(10):e76787. PubMed ID: 24116157
[TBL] [Abstract][Full Text] [Related]
29. APC gene promoter aberrant methylation in serum as a biomarker for breast cancer diagnosis: A meta-analysis.
Qian X; Ruan L
Thorac Cancer; 2018 Feb; 9(2):284-290. PubMed ID: 29297603
[TBL] [Abstract][Full Text] [Related]
30. Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis.
Lin Z; Neiswender J; Fang B; Ma X; Zhang J; Hu X
Oncotarget; 2017 Apr; 8(16):26625-26636. PubMed ID: 28460452
[TBL] [Abstract][Full Text] [Related]
31. [Methylation of the promoter region of the RASSF1A gene, a candidate tumor suppressor, in primary epithelial tumors].
Loginov VI; Maliukova AV; Seregin IuA; Khodyrev DS; Kazubskaia TP; Ermilova VD; Gar'kavtseva RF; Kiselev LL; Zabarovskiĭ ER; Braga EA
Mol Biol (Mosk); 2004; 38(4):654-67. PubMed ID: 15456137
[TBL] [Abstract][Full Text] [Related]
32. Promoter methylation of the RASSF1A gene may contribute to colorectal cancer susceptibility: a meta-analysis of cohort studies.
Wang HL; Liu P; Zhou PY; Zhang Y
Ann Hum Genet; 2014 May; 78(3):208-16. PubMed ID: 24621386
[TBL] [Abstract][Full Text] [Related]
33. High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions.
Martins AT; Monteiro P; Ramalho-Carvalho J; Costa VL; Dinis-Ribeiro M; Leal C; Henrique R; Jerónimo C
Breast Cancer Res Treat; 2011 Aug; 129(1):1-9. PubMed ID: 20842524
[TBL] [Abstract][Full Text] [Related]
34. The diagnostic role of microRNA-34a in breast cancer: a systematic review and meta-analysis.
Imani S; Zhang X; Hosseinifard H; Fu S; Fu J
Oncotarget; 2017 Apr; 8(14):23177-23187. PubMed ID: 28423566
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic Value of the Methylation of Multiple Gene Promoters in Serum in Hepatitis B Virus-Related Hepatocellular Carcinoma.
Dong X; Hou Q; Chen Y; Wang X
Dis Markers; 2017; 2017():2929381. PubMed ID: 28951629
[TBL] [Abstract][Full Text] [Related]
36. Potential of RASSF1A promoter methylation as biomarker for endometrial cancer: A systematic review and meta-analysis.
Pabalan N; Kunjantarachot A; Ruangpratheep C; Jarjanazi H; Christofolini DM; Barbosa CP; Bianco B
Gynecol Oncol; 2017 Sep; 146(3):603-608. PubMed ID: 28669560
[TBL] [Abstract][Full Text] [Related]
37. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
38. The relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma: A meta-analysis and bioinformatics.
Shao C; Dai W; Li H; Tang W; Jia S; Wu X; Luo Y
PLoS One; 2017; 12(2):e0171676. PubMed ID: 28207831
[TBL] [Abstract][Full Text] [Related]
39. Association between HIC1 and RASSF1A promoter hypermethylation with MTHFD1 G1958A polymorphism and clinicopathological features of breast cancer in Iranian patients.
Rasti M; Tavasoli P; Monabati A; Entezam M
Iran Biomed J; 2009 Oct; 13(4):199-206. PubMed ID: 19946345
[TBL] [Abstract][Full Text] [Related]
40. Signaling pathways and clinical application of RASSF1A and SHOX2 in lung cancer.
Li N; Zeng Y; Huang J
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1379-1393. PubMed ID: 32266538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
